Results 71 to 80 of about 351,289 (236)

Management and Outcomes in Confirmed or Suspected Acute Symptomatic Seizure: Role of Structured Outpatient Care

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Post‐discharge management and outcomes of acute symptomatic seizures (ASyS) remain underexplored. We analyzed post‐discharge ASM management and outcomes in ASyS patients undergoing continuous EEG (cEEG), including the role of outpatient care through a post‐acute symptomatic seizure (PASS) clinic. Methods We performed a single‐center,
Vineet Punia, MarieElena Byrnes, Nicolas R. Thompson, Neishay Ayub, Clio Rubinos, Sahar Zafar, Adithya Sivaraju, Zhong Ying, Jessica R. Fesler, Stephen Hantus, Post‐Acute Symptomatic Seizure Investigation and Outcomes Network (PASSION) investigators   +10 more
wiley   +1 more source

The cost of drugs [PDF]

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2017
openaire   +2 more sources

Patients' Global Impression of Change (PGIC) Score Compared to Monthly Migraine Days to Evaluate Treatment Persistence With Anti‐CGRP Monoclonal Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This study assessed whether continued treatment with anti‐CGRP monoclonal antibodies (mAbs) is driven more by reductions in monthly migraine days (MMDs) or patients' global impression of change (PGIC), a patient‐reported outcome. Among 169 patients treated with anti‐CGRP mAbs, 21.3% discontinued due to ineffectiveness. PGIC responders (≥ 5) at
Marina Romozzi, Catello Vollono, Paolo Calabresi, Francesco De Cesaris, Luigi Francesco Iannone   +4 more
wiley   +1 more source

High cost drugs [PDF]

Journal of Prescribing Practice, 2021
openaire   +2 more sources

Variations in compliance among hypertensive patients by drug class: implications for health care costs

, 1997
John A. Rizzo, W. Robert Simons
openalex   +1 more source

Practical approach to determining costs and frequency of adverse drug events in a health care network [PDF]

, 2001
Bonnie L. Senst, Louis E. Achusim, Robert Genest, Laurey A. Cosentino, Corey C. Ford, James A. Little, Sabrina J. Raybon, David W. Bates   +7 more
openalex   +1 more source

The Impact of Diabetes and Metabolic Syndrome Burden on Pain, Neuropathy Severity and Fiber Type

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Determine the association between diabetes and metabolic syndrome (MetS) burden (number of MetS criteria fulfilled) and pain, neuropathy severity, and fiber type involvement in individuals with established polyneuropathy. Methods The Peripheral Neuropathy Research Registry was queried for individuals with type 1 and type 2 diabetes ...
Long Davalos, Brian C. Callaghan, Lavanya Muthukumar, Simone Thomas, Evan L. Reynolds, A. Gordon Smith, J. Robinson Singleton, Ahmet Höke, Senda Ajroud‐Driss, Mazen M. Dimachkie, Stefanie Geisler, David M. Simpson, PNRR Study Group, Amro M. Stino   +13 more
wiley   +1 more source

Drug Costs: What Can Infectious Diseases Physicians Do? [PDF]

J Infect Dis, 2020
Kapadia SN, Gulick RM.
europepmc   +1 more source

An Analysis for IDH‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Purpose There is ongoing debate regarding the therapeutic approach and prognosis for IDH‐mutant grade 4 astrocytoma, a newly defined subtype of diffuse glioma in the 2021 WHO classification system for central nervous system tumors (WHO CNS 5). The aim of this study was to explore the clinical outcome and prognosticators for newly diagnosed IDH‐
Xianxin Qiu, Liping Liang, Lingchao Chen, Pengjie Hong, Wanzun Lin, Jiabing Liu, Zhirui Zhou, Wenjia Zhu, Tianqi Wu, Mingyuan Pan, Yihua Zhong, Jing Gao, Zhiyong Qin, Yang Wang   +13 more
wiley   +1 more source

Review of Current Policy Strategies to Reduce US Cancer Drug Costs. [PDF]

J Clin Oncol, 2020
Green AK, Ohn JA, Bach PB.
europepmc   +1 more source